Tetraneuron is concentrating its research on E2F4, a cell cycle regulator extensively related to Alzheimer’s disease.
E2F4DN is a modified variant of E2F4 that cannot be phosphorylated. The blocking of this phosphorylation prevents the start of neuronal tetraploidy, restoring the homeostasis and the neuronal function in the brain.
TETRANEURON AAV-E2F4 is a safe product that is only expressed under the control of a neuronal promoter, improving several pathological mechanisms of Alzheimer’s disease.
We have developed a disruptive, highly innovative technology, patented in the United States, the European Union and Japan.
Tetraneuron is working on the phosphorylation of E2F4 during the earliest stages of Alzheimer’s disease, analysing the presence of phosphorylated E2F4 in blood serum as an early biomarker for this disease.
This technology has been patented internationally.
Pathological aspects of neuronal hyperploidization in Alzheimer’s disease evidenced by computer simulation (2020)Leer artículo
Primary neurons can enter M-phase (2019)Leer artículo
Cell cycle reentry triggers hyperploidization and synaptic dysfunction followed by delayed cell death in differentiated cortical neurons (2018)Leer artículo
Neuronal tetraploidy in Alzheimer and Aging (2017)Leer artículo
Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer’s-associated neuropathology (2017)Leer artículo
Strand-specific CpG hemimethylation, a novel epigenetic modification functional for gene silencing (2017)Leer artículo
Nerve Growth Factor-Induced Cell Cycle Reentry in Newborn Neurons Is Triggered by p38MAPK-Dependent E2F4 Phosphorylation (2012)Leer artículo
Somatic tetraploidy in specific chick retinal ganglion cells induced by nerve growth factor (2010)Leer artículo
Induction of cell death by endogenous nerve growth factor through its p75 receptor (1996)Leer artículo